stooocks.com

Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.

PharmaNutra S.p.A.

Italy · Milan: PHN.MI · Market cap: · P/E: · P/S:

PharmaNutra makes and sells nutritional supplements and medical devices, mainly iron supplements and muscle-support products, through pharmacies and distributors around the world.

PharmaNutra is an Italian company that sells nutritional supplements and small medical devices — pills, gels, and patches that people buy at the pharmacy rather than prescription drugs. Its customers are mostly pharmacists, who stock the products on their shelves, plus distributors who move them into other countries.

Its best-known product is SiderAL, an iron supplement. The clever part is how it gets iron into the body: the iron is wrapped in a phospholipid coating, which lets it dissolve in water and be absorbed without the stomach upset that ordinary iron pills often cause. Iron deficiency is a huge, unglamorous problem, especially for women, pregnant people, and athletes, and standard iron tablets frequently make people constipated or nauseous. PharmaNutra's pitch is simple: same benefit, fewer side effects. A second big line, Cetilar, targets muscles and joints, sold as creams and patches and popular with amateur and professional athletes. The company also makes devices and supplements for other needs, but iron and muscle care are the core. The business model is attractive because supplements are cheap to make relative to their shelf price, and pharmacies are loyal, repeat-driven channels. Once a pharmacist recommends a brand and a customer likes it, they tend to come back. PharmaNutra invests heavily in clinical studies to back up its claims — unusual for the supplement world — which gives it credibility with pharmacists and a moat against copycats. It also patents its delivery technology, so rivals can't simply clone the key products.


Growth has come from expanding abroad, especially in Europe and the US, where the iron supplement market is enormous. The main risks are familiar ones: regulators scrutinizing health claims, competition from cheaper generic iron pills, and the fact that a lot of revenue depends on a small number of hero products. PharmaNutra is based in Pisa, Italy, and has been listed on the Milan stock exchange since 2017.

Saved answer · last researched 15 Nov 2026